原蛋白签名为乳腺癌的分期增加了具有预后意义的信息
1Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, China.
ESMO open
|November 22, 2024
概括
完整的原体签名通过识别高风险患者和完善预后来改善乳腺癌的分期. 这种新的方法增强了目前的瘤结节转移 (TNM) 系统,以改善患者分层.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 生物标志物 生物标志物
背景情况:
- 瘤相关原签名 (TACS) 是乳腺癌的已知预后因素.
- 结合瘤结节转移 (TNM) 阶段测定系统,完整的原体特征 (TACS,基于TACS的原体显微特征 [TCMF1],以及基于TACS的核特征 [TCMF2]) 的预后价值以前尚不清楚.
研究的目的:
- 调查完整的原体签名是否为目前的乳腺癌TNM分期系统提供了额外的预后信息.
- 开发一个修改后的分期系统,包括完整的原体签名.
主要方法:
- 总共分析了来自培训,内部验证和外部验证队伍的941名乳腺癌患者.
- 使用多光子显微镜 (MPM) 评估了TACS和TCMF1.
- 从血素和素图像中提取了TCMF2,并将这些组件结合起来,形成一个完整的原签名得分,用于重新分类TNM阶段.
主要成果:
- 完整的原体签名重新分类了患者,将一些患者"降级"到II/III阶段,并将那些患有I阶段瘤的患者"升级".
- 与标准TNM系统相比,修改后的TNM分期系统,包括原签名,在所有三个队列中显著提高了患者分层能力.
- 修改后的系统在所有队列中显示了曲线下面积 (AUC) 的增加,这表明预测性能优越.
结论:
- 完整的原体签名是乳腺癌生存结果的独立预测指标.
- 这种签名为乳腺癌分期增加了重要的生物信息.
- 这些发现支持将完整的原签名纳入临床实践,以改善乳腺癌预后.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...